MEK inhibition invigorates chemoimmunotherapy by tumor mitophagy-induced CXCL10 expression

A recent study by Limagne et al.(1) in Cancer Cell demonstrates that addition of MEK inhibitor to standard-of-care platinum/pemetrexed promotes mitophagy-dependent CXCL10 expression via optineurin and TLR9. Tumor cell secretion of CXCL10 produces T cell recruitment and enhances immunotherapy efficac...

Descripción completa

Detalles Bibliográficos
Autores principales: Rodriguez, B. Leticia, Gibbons, Don L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Spotlight
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8784763/
https://www.ncbi.nlm.nih.gov/pubmed/35106515
http://dx.doi.org/10.1016/j.xcrm.2021.100506

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8784763/
https://www.ncbi.nlm.nih.gov/pubmed/35106515
http://dx.doi.org/10.1016/j.xcrm.2021.100506

Ejemplares similares